BIOC - Biocept Inc Stock Price, Fair Value and News

0.07USD+0.04 (+133.33%)Market Closed

Market Summary

USD0.07+0.04

Market Closed

133.33%

BIOC Stock Price

View Fullscreen

BIOC RSI Chart

BIOC Valuation

Market Cap

183.8K

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.01

EV/EBITDA

0.22

Price/Free Cashflow

-0.01

BIOC Price/Sales (Trailing)

BIOC Profitability

Operating Margin

39.43%

EBT Margin

-118.85%

Return on Equity

-10.6K%

Return on Assets

-138.48%

Free Cashflow Yield

-9.9K%

BIOC Fundamentals

BIOC Revenue

Revenue (TTM)

25.9M

BIOC Earnings

Earnings (TTM)

-30.6M

Breaking Down BIOC Revenue

Last 7 days

-40%

Last 30 days

-50%

Last 90 days

-97.9%

Trailing 12 Months

-94.8%

How does BIOC drawdown profile look like?

BIOC Financial Health

Current Ratio

1.81

BIOC Investor Care

Shares Dilution (1Y)

366.80%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	63.4M	57.2M	40.7M	25.9M
2021	43.8M	54.9M	65.8M	61.2M
2020	6.0M	5.7M	10.7M	27.5M
2019	3.5M	3.8M	4.6M	5.5M
2018	4.2M	3.7M	3.4M	3.3M
2017	4.7M	5.3M	5.4M	5.1M
2016	681.3K	1.3M	2.1M	3.2M
2015	223.0K	312.7K	467.2K	609.9K
2014	134.1K	133.9K	133.6K	133.4K
2013	134.1K	128.4K	136.4K	134.2K
2012	0	0	0	109.3K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biocept Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 09, 2021	hale david f	sold	-288	4.0664	-71.00	-
Dec 09, 2021	hale david f	sold	-44.7887	4.0717	-11.00	-
Dec 09, 2021	hale david f	sold	-1,473	4.0602	-363	-
Jun 12, 2020	hale david f	sold	-308	0.555	-556	-
Jun 12, 2020	hale david f	sold	-246	0.5545	-445	-
Jun 12, 2020	hale david f	sold	-88.6902	0.5578	-159	-

Which funds bought or sold BIOC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-17,000	-	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-15,898	-	-%
Feb 14, 2024	Alyeska Investment Group, L.P.	sold off	-100	-147,059	-	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	sold off	-100	-13,130	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-4,752	-	-%
Feb 09, 2024	UBS Group AG	sold off	-100	-155	-	-%
Jan 25, 2022	REILLY FINANCIAL ADVISORS, LLC	new	-	1,000	1,000	-%

Are Funds Buying or Selling BIOC?

Are funds buying BIOC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIOC

No. of Funds

Unveiling Biocept Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jun 02, 2023	lind global fund ii lp	9.9%	147,294	SC 13G
Jan 05, 2021	sabby management, llc	12.%	0	SC 13G/A
Mar 13, 2020	intracoastal capital, llc	0.6%	607,279	SC 13G
Mar 04, 2020	sabby management, llc	12.%	0	SC 13G
Feb 14, 2020	anson funds management lp	4.8%	2,387,910	SC 13G/A
Feb 11, 2020	intracoastal capital, llc	4.5%	1,973,168	SC 13G/A
Jan 15, 2020	empery asset management, lp	4.99%	2,309,027	SC 13G/A
Jan 02, 2020	sabby management, llc	12.%	0	SC 13G/A

Peers (Alternatives to Biocept Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	186.4B	23.7B	0.65%	7.71%	42.34	7.85	-8.94%	-35.91%
A	43.3B	6.7B	-1.53%	13.34%	35.04	6.43	-2.81%	-6.58%
IDXX	41.4B	3.7B	-3.65%	3.24%	47.73	11.1	8.57%	23.94%
DGX	15.6B	9.3B	4.08%	4.33%	18.48	1.68	-3.29%	6.68%
MEDP	12.4B	2.0B	-1.38%	89.95%	39.58	6.3	25.57%	21.62%
CRL	11.8B	4.1B	-10.52%	23.51%	26.83	2.86	0.49%	-11.59%
NTRA	11.7B	1.2B	-1.98%	86.58%	-32.11	9.71	39.26%	33.08%
EXAS	10.0B	2.5B	-27.08%	-31.22%	-41.6	3.94	15.21%	53.51%
MID-CAP
NEOG	2.7B	929.2M	-4.68%	-27.52%	1.7K	2.87	28.93%	111.61%
GH	2.4B	603.7M	1.25%	-29.49%	-5.16	3.94	25.21%	30.68%
SMALL-CAP
CDNA	772.4M	275.1M	11.16%	28.75%	-4.22	2.81	-13.93%	-126.97%
ACRS	83.4M	31.1M	3.36%	-85.16%	-1.08	2.68	0.95%	19.75%
AWH	36.7M	9.2M	-0.97%	-31.78%	-2.2	4.01	11.85%	44.15%
APDN	3.4M	5.5M	784.62%	219.44%	-0.28	0.62	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Biocept Inc News

Latest updates

Biocept Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-12.5%	589,000	673,000	840,250	1,007,500	5,819,000	19,945,000	13,976,000	17,470,000	12,047,000	17,756,000	18,510,838	6,586,144	917,471	1,446,549	1,783,742	1,529,262	1,191,323	1,024,239	859,526	761,591	822,238
Cost Of Revenue	-15.8%	2,550,000	3,028,000	4,307,500	5,776,000	8,023,000	10,334,000	10,031,000	11,265,000	7,462,000	9,006,000	10,013,101	5,859,370	2,517,902	2,946,858	2,872,098	2,832,735	2,673,323	2,599,364	2,435,262	2,481,916	2,699,671
Costs and Expenses	-13.7%	6,703,000	7,771,000	8,875,500	11,164,000	15,708,000	22,094,000	16,751,500	18,020,000	13,795,000	15,092,000	16,544,863	11,404,929	7,351,128	7,629,082	7,434,813	7,158,996	7,112,645	6,879,052	6,797,690	6,769,574	6,861,100
S&GA Expenses	-65.0%	250,000	715,000	837,500	975,000	1,656,000	3,658,000	2,514,000	1,938,000	1,945,000	1,923,000	2,167,133	1,434,481	1,333,271	1,465,115	1,489,216	1,462,335	1,614,732	1,374,560	1,440,798	1,404,192	1,433,174
R&D Expenses	-60.7%	409,000	1,040,000	1,259,500	1,366,000	1,729,000	1,846,000	1,477,000	1,303,000	1,137,000	1,043,000	1,230,867	1,087,741	1,588,716	1,312,676	1,161,905	1,163,546	1,148,280	1,223,291	1,288,957	1,089,746	1,019,285
EBITDA Margin	18.3%	-1.11	-1.36	-1.17	-0.57	-0.24	-0.09	-0.01	0.06	-0.01	-0.12	-0.60	-2.25	-4.41	-	-	-	-	-	-	-	-
Interest Expenses	8.7%	50,000	46,000	47,000	52,500	155,000	61,000	70,905	74,499	79,692	65,000	64,109	59,549	55,646	56,696	62,409	62,028	63,574	61,974	80,299	63,764	84,239
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,147	-	-
Earnings Before Taxes	49.2%	-3,631,000	-7,144,000	-9,833,000	-10,125,000	-10,044,000	-2,210,000	-2,845,500	-625,000	-1,828,000	2,599,000	1,901,975	-4,878,334	-6,489,303	-8,341,338	-5,713,479	-5,691,762	-7,816,012	-5,916,787	-6,012,426	-6,047,784	-6,153,101
EBT Margin	17.3%	-1.19	-1.44	-1.25	-0.62	-0.27	-0.12	-0.04	0.03	-0.04	-0.16	-0.65	-2.37	-4.62	-	-	-	-	-	-	-	-
Net Income	49.2%	-3,631,000	-7,144,000	-9,708,000	-10,125,000	-10,044,000	-2,210,000	-2,971,000	-625,000	-1,827,000	2,599,000	12,284,649,821	-4,878,334,000	-6,489,303	-8,341,338	-5,713,478	-5,691,762	-7,816,012	-5,916,787	-6,014,312	-6,047,784	-6,153,101
Net Income Margin	17.3%	-1.18	-1.43	-1.24	-0.62	-0.28	-0.12	-0.05	186	134	169	269	-456	-4.62	-	-	-	-	-	-	-	-
Free Cashflow	49.4%	-3,183,000	-6,285,000	-4,378,000	-4,431,000	-4,257,000	-1,030,000	974,000	-835,000	1,847,000	132,000	-1,904,568	-6,742,609	-6,708,456	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Assets	-3.9%	22.00	23.00	31.00	42.00	53.00	62.00	60.00	62.00	51.00	50.00	47.00	33.00	33.00	30.00	18.00	15.00	20.00	22.00	9.00	15.00	8.00
Current Assets	-2.5%	9.00	9.00	16.00	27.00	39.00	48.00	46.00	47.00	36.00	35.00	33.00	29.00	29.00	26.00	14.00	11.00	16.00	17.00	6.00	12.00	5.00
Cash Equivalents	-2.1%	7.00	7.00	13.00	18.00	23.00	28.00	29.00	28.00	20.00	14.00	14.00	17.00	24.00	21.00	9.00	7.00	13.00	15.00	3.00	9.00	3.00
Inventory	-21.7%	1.00	1.00	1.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	2.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Net PPE	-4.7%	2.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	2.00	1.00	1.00	1.00	3.00	3.00	3.00
Liabilities	6.1%	22.00	21.00	22.00	24.00	26.00	25.00	23.00	23.00	21.00	24.00	24.00	11.00	7.00	7.00	7.00	7.00	7.00	8.00	6.00	6.00	6.00
Current Liabilities	11.6%	5.00	4.00	6.00	7.00	10.00	14.00	12.00	11.00	10.00	12.00	12.00	10.00	6.00	6.00	6.00	6.00	6.00	6.00	5.00	4.00	5.00
Shareholder's Equity	-88.1%	0.00	2.00	9.00	18.00	28.00	37.00	37.00	39.00	29.00	27.00	24.00	21.00	26.00	23.00	11.00	8.00	13.00	14.00	3.00	9.00	3.00
Retained Earnings	-1.2%	-309	-305	-298	-288	-278	-268	-266	-263	-262	-260	-263	-265	-260	-254	-245	-239	-234	-226	-220	-214	-207
Additional Paid-In Capital	0.5%	310	308	307	307	306	306	304	302	292	288	287	287	287	277	257	248	247	240	223	223	210
Shares Outstanding	306.0%	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	16.00	-	-	-	60.00	-	-	-	93.00	-	-	-	26.00	-	-	-	14.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	50.2%	-3,086	-6,194	-4,242	-4,075	-4,040	-932	1,564	-685	1,967	844	-1,115	-6,713	-6,691	-5,278	-5,471	-5,607	-6,722	-5,247	-5,418	-5,454	-5,906
Share Based Compensation	-33.9%	209	316	421	462	585	1,759	807	701	494	460	437	167	194	143	245	298	225	102	111	113	174
Cashflow From Investing	75.8%	-22.00	-91.00	-136	-356	-217	-98.00	-590	-150	-120	-712	-802	-28.87	-16.95	-18.51	-437	-211	-53.58	-32.90	-	-72.90	-18.38
Cashflow From Financing	1731.5%	2,967	162	-746	-476	-381	-268	192	9,082	3,406	-302	-584	-452	9,269	17,489	8,671	-232	4,604	16,619	-114	11,915	-778

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BIOC Income Statement

2023-06-30

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Net revenues	$ 589	$ 5,819	$ 1,262	$ 25,763
Costs and expenses:
Cost of revenues	2,550	8,023	5,578	18,357
Research and development expenses	409	1,729	1,449	3,574
General and administrative expenses	3,494	4,300	6,482	10,556
Sales and marketing expenses	250	1,656	965	5,314
Total costs and expenses	6,703	15,708	14,474	37,801
Loss from operations	(6,114)	(9,889)	(13,212)	(12,038)
Other income (expense):
Interest expense, net	(50)	(155)	(96)	(217)
Other income, net	91		91
Change in fair value of warrant liability	2,442		2,442
Total other income (expense):	2,483	(155)	2,437	(217)
Loss before income taxes	(3,631)	(10,044)	(10,775)	(12,255)
Net loss	(3,631)	(10,044)	(10,775)	(12,255)
Net loss attributable to common stockholders	$ (3,631)	$ (10,044)	$ (10,775)	$ (12,255)
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders:
Basic	1,036,529	563,528	813,180	562,561
Diluted	1,036,529	563,528	813,180	562,561
Net loss per common share:
Basic	$ (3.50)	$ (17.82)	$ (13.25)	$ (21.78)
Diluted	$ (3.50)	$ (17.82)	$ (13.25)	$ (21.78)

BIOC Balance Sheet

2023-06-30

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 6,633	$ 12,897
Accounts receivable	800	2,151
Inventories, net	551	757
Prepaid expenses and other current assets	876	538
Total current assets	8,860	16,343
Fixed assets, net	2,395	2,572
Lease right-of-use asset - operating	8,190	8,486
Lease right-of-use assets - finance	2,272	3,086
Other non-current assets	386	386
Total assets	22,103	30,873
Current liabilities:
Accounts payable	1,467	1,523
Accrued liabilities	1,529	2,249
Current portion of lease liability - operating	565	518
Current portion of lease liabilities - finance	815	1,099
Financed insurance premiums	526	117
Total current liabilities	4,902	5,506
Non-current portion of lease liability - operating	8,849	9,175
Non-current portion of lease liabilities - finance	836	1,200
Payor liability	6,149	6,132
Warrant liability	1,077
Total liabilities	21,813	22,013
Commitments and contingencies (see Note 11)
Stockholders' equity:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized; 2,090 shares issued and outstanding at June 30, 2023 and December 31, 2022
Common stock, $0.0001 par value, 150,000,000 shares authorized; 2,407,381 shares and 568,994 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively.
Additional paid-in capital	309,503	307,298
Accumulated deficit	(309,213)	(298,438)
Total stockholders' equity	290	8,860
Total liabilities and stockholders' equity	$ 22,103	$ 30,873

About Biocept Inc

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

CEO	Mr. Antonino Morales
WEBSITE	https://biocept.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	50

Biocept Inc Frequently Asked Questions

What is the ticker symbol for Biocept Inc? What does BIOC stand for in stocks?

BIOC is the stock ticker symbol of Biocept Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biocept Inc (BIOC)?

As of Tue Dec 26 2023, market cap of Biocept Inc is 183.82 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIOC stock?

You can check BIOC's fair value in chart for subscribers.

What is the fair value of BIOC stock?

You can check BIOC's fair value in chart for subscribers. The fair value of Biocept Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biocept Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIOC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biocept Inc a good stock to buy?

The fair value guage provides a quick view whether BIOC is over valued or under valued. Whether Biocept Inc is cheap or expensive depends on the assumptions which impact Biocept Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIOC.

What is Biocept Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 26 2023, BIOC's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIOC PE ratio will change depending on the future growth rate expectations of investors.